-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the Shanghai real-Jun Biotechnology Co.
management
JS201 is a bi-functional fusion protein developed by Junshi Biotech using its proprietary technology, which can simultaneously target PD-1 and TGF-β (transforming growth factor-β).
JS201 is the first product that targets PD-1/TGF-β to be approved for clinical trials in China.
Junshi Biosciences is the first Chinese pharmaceutical company in China to obtain an anti-PD-1 monoclonal antibody sales license.
FDA
Currently, Junshi Biosciences has more than 2,000 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing and Guangzhou).
Original source:
Original source:https://target="_blank" rel="noopener">https:// style="vertical-align: inherit;"> https:// leave a message here